Neuralstem Stock Price, News & Analysis (NASDAQ:CUR)

$1.53 -0.04 (-2.56 %)
(As of 02/23/2018 04:00 PM ET)
Previous Close$1.53
Today's Range$1.46 - $1.55
52-Week Range$0.88 - $6.60
Volume156,956 shs
Average Volume155,531 shs
Market Capitalization$23.63 million
P/E RatioN/A
Dividend YieldN/A
Beta1.54

About Neuralstem (NASDAQ:CUR)

Neuralstem logoNeuralstem, Inc. (Neuralstem) is a clinical-stage biopharmaceutical company. The Company is engaged in research, development and commercialization of central nervous system therapies based on its human neuronal stem cells and its stem-cell derived small molecule compounds. The Company has approximately three assets: its NSI-189 small molecule program, its NSI-566 stem cell therapy program and its chemical entity screening platform. The Company's technology allows the commercial-scale production of multiple types of central nervous system stem cells, which are under development for the treatment of central nervous system diseases and conditions. The Company is developing NSI-189 for the treatment of major depressive disorder (MDD) and other psychiatric and/or cognitive impairment indications associated with hippocampal atrophy. The Company's NSI-566 is indicated for amyotrophic lateral sclerosis (ALS), chronic spinal cord injury and motor deficits due to ischemic stroke.

Receive CUR News and Ratings via Email

Sign-up to receive the latest news and ratings for CUR and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceuticals
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:CUR
CUSIPN/A
Phone301-366-4841

Debt

Debt-to-Equity RatioN/A
Current Ratio8.03%
Quick Ratio8.03%

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$20,000.00
Price / Sales1,155.19
Cash FlowN/A
Price / CashN/A
Book Value$1.03 per share
Price / Book1.48

Profitability

Trailing EPSN/A
Net Income$-21,070,000.00
Net Margins-154,347.81%
Return on Equity-148.94%
Return on Assets-84.85%

Miscellaneous

Employees11
Outstanding Shares15,150,000

Neuralstem (NASDAQ:CUR) Frequently Asked Questions

What is Neuralstem's stock symbol?

Neuralstem trades on the NASDAQ under the ticker symbol "CUR."

How were Neuralstem's earnings last quarter?

Neuralstem, Inc. (NASDAQ:CUR) released its quarterly earnings data on Tuesday, August, 8th. The company reported ($0.39) EPS for the quarter, beating the Thomson Reuters' consensus estimate of ($9.49) by $9.10. Neuralstem had a negative net margin of 154,347.81% and a negative return on equity of 148.94%. View Neuralstem's Earnings History.

When will Neuralstem make its next earnings announcement?

Neuralstem is scheduled to release their next quarterly earnings announcement on Wednesday, March, 21st 2018. View Earnings Estimates for Neuralstem.

Where is Neuralstem's stock going? Where will Neuralstem's stock price be in 2018?

0 brokers have issued 1-year price objectives for Neuralstem's shares. Their forecasts range from $1.91 to $1.91. On average, they anticipate Neuralstem's share price to reach $1.91 in the next year. View Analyst Ratings for Neuralstem.

Who are some of Neuralstem's key competitors?

Who are Neuralstem's key executives?

Neuralstem's management team includes the folowing people:

  • Richard J. Daly, Chairman of the Board, President, Chief Executive Officer, Interim Principal Financial and Accounting Officer (Age 56)
  • David Recker M.D., Chief Medical Officer (Age 58)
  • Xi Chen, Director
  • Cristina Csimma, Director
  • Scott V. Ogilvie, Independent Director (Age 62)
  • William Clyde Oldaker, Independent Director (Age 75)
  • Sandford D. Smith, Independent Director (Age 70)

How do I buy Neuralstem stock?

Shares of Neuralstem can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Neuralstem's stock price today?

One share of Neuralstem stock can currently be purchased for approximately $1.53.

How big of a company is Neuralstem?

Neuralstem has a market capitalization of $23.63 million and generates $20,000.00 in revenue each year. Neuralstem employs 11 workers across the globe.

How can I contact Neuralstem?

Neuralstem's mailing address is 20271 Goldenrod Lane, Germantown MD, 20876. The company can be reached via phone at 301-366-4841 or via email at [email protected]


MarketBeat Community Rating for Neuralstem (CUR)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  158 (Vote Outperform)
Underperform Votes:  113 (Vote Underperform)
Total Votes:  271
MarketBeat's community ratings are surveys of what our community members think about Neuralstem and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Neuralstem (NASDAQ:CUR) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: N/AN/AN/ABuy
Consensus Rating Score: N/AN/AN/A3.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $1.91$1.91$3.18$2.79
Price Target Upside: 0.00% downside0.00% downside0.00% downside12.16% downside

Neuralstem (NASDAQ:CUR) Consensus Price Target History

Price Target History for Neuralstem (NASDAQ:CUR)

Neuralstem (NASDAQ:CUR) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
1/11/2018S&P Equity ResearchLower Price Target$2.26 -> $1.91LowView Rating Details
11/10/2016Roth CapitalReiterated RatingBuy$1.20N/AView Rating Details
11/7/2016AegisInitiated CoverageBuyN/AView Rating Details
10/4/2016Brean CapitalInitiated CoverageBuy$4.00N/AView Rating Details
(Data available from 2/24/2016 forward)

Earnings

Neuralstem (NASDAQ:CUR) Earnings History and Estimates Chart

Earnings by Quarter for Neuralstem (NASDAQ:CUR)

Neuralstem (NASDAQ CUR) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/21/2018N/AView Earnings Details
11/13/2017Q3 2017($0.18)ViewN/AView Earnings Details
8/8/2017Q2 2017($9.49)($0.39)ViewN/AView Earnings Details
5/10/2017Q1 2017($0.43)ViewN/AView Earnings Details
11/8/2016Q3($0.03)($0.05)ViewN/AView Earnings Details
8/11/2016Q2($0.05)($0.04)$2.50 million$2.50 millionViewN/AView Earnings Details
5/9/2016Q1($0.06)($0.07)ViewN/AView Earnings Details
3/14/2016Q4($0.07)($0.05)ViewN/AView Earnings Details
11/9/2015Q315($0.07)($0.06)ViewN/AView Earnings Details
8/10/2015Q2($0.06)($0.06)ViewN/AView Earnings Details
5/8/2015Q115($0.07)($0.06)$2.92 millionViewN/AView Earnings Details
4/20/2015($0.07)($0.06)ViewN/AView Earnings Details
3/16/2015Q4 2014($0.05)($0.06)$0.01 millionViewN/AView Earnings Details
11/7/2014Q314($0.05)($0.05)$0.01 millionViewN/AView Earnings Details
8/8/2014Q214($0.05)($0.08)$0.10 million$0.01 millionViewN/AView Earnings Details
5/12/2014Q114($0.05)($0.04)$0.35 million$0.00 millionViewN/AView Earnings Details
3/10/2014Q4 2013($0.06)($0.04)ViewN/AView Earnings Details
11/11/2013Q3($0.04)($0.09)ViewN/AView Earnings Details
8/9/2013Q213($0.05)($0.09)$0.08 million$0.00 millionViewN/AView Earnings Details
5/10/2013Q1 2013($0.52)($0.52)$0.10 million$0.10 millionViewN/AView Earnings Details
3/15/2013Q4 2012($0.52)($0.39)ViewN/AView Earnings Details
11/9/2012Q312($0.04)($0.04)ViewN/AView Earnings Details
8/10/2012Q2 2012($0.78)($0.57)ViewN/AView Earnings Details
5/9/2012Q1 2012($0.62)ViewN/AView Earnings Details
3/29/2012Q4 2011($0.78)($0.68)ViewN/AView Earnings Details
11/9/2011Q3 2011($0.91)($0.86)ViewN/AView Earnings Details
8/10/2011Q2 2011($0.99)ViewN/AView Earnings Details
5/10/2011Q1 2011($1.30)($0.96)ViewN/AView Earnings Details
3/16/2011Q4 2010($1.30)($0.65)ViewN/AView Earnings Details
11/16/2010Q3 2010($1.43)($1.16)ViewN/AView Earnings Details
8/16/2010Q2 2010($1.40)ViewN/AView Earnings Details
5/17/2010Q1 2010($1.27)ViewN/AView Earnings Details
3/31/2010Q4 2009($1.04)ViewN/AView Earnings Details
11/17/2009Q3 2009($1.91)ViewN/AView Earnings Details
8/13/2009Q2 2009($1.05)ViewN/AView Earnings Details
5/15/2009Q1 2009($1.07)ViewN/AView Earnings Details
3/31/2009Q4 2008($1.43)ViewN/AView Earnings Details
11/13/2008Q3 2008($1.29)ViewN/AView Earnings Details
8/14/2008Q2 2008($1.20)ViewN/AView Earnings Details
5/15/2008Q1 2008($0.94)ViewN/AView Earnings Details
3/28/2008Q4 2007($1.17)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

Neuralstem (NASDAQ:CUR) Earnings Estimates

No earnings estimates for this company have been tracked by MarketBeat.com

Dividends

Dividend History for Neuralstem (NASDAQ:CUR)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Neuralstem (NASDAQ CUR) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 19.25%
Institutional Ownership Percentage: 6.76%
Insider Trades by Quarter for Neuralstem (NASDAQ:CUR)
Insider Trades by Quarter for Neuralstem (NASDAQ:CUR)

Neuralstem (NASDAQ CUR) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
5/17/2017Richard J DalyCEOBuy7,500$4.00$30,000.0023,312View SEC Filing  
3/24/2017Jones Jonathan Brian LloydCFOBuy5,455$5.50$30,002.507,859View SEC Filing  
2/24/2017Richard J DalyCEOBuy2,591$3.86$10,001.2615,812View SEC Filing  
1/25/2017Richard J DalyCEOBuy2,841$3.52$10,000.3213,221View SEC Filing  
12/23/2016Richard J DalyCEOBuy32,259$0.31$10,000.29134,939View SEC Filing  
11/25/2016Richard J DalyCEOBuy35,715$0.28$10,000.20102,680View SEC Filing  
10/25/2016Richard J DalyCEOBuy35,715$0.28$10,000.2066,965View SEC Filing  
9/23/2016Richard J DalyCEOBuy31,250$0.32$10,000.0031,250View SEC Filing  
11/16/2015Karl JoheInsiderSell25,000$1.09$27,250.00826,304View SEC Filing  
11/9/2015Karl JoheInsiderSell25,000$1.18$29,500.00851,304View SEC Filing  
11/2/2015Karl JoheInsiderSell25,000$1.17$29,250.00876,304View SEC Filing  
10/26/2015Karl JoheInsiderSell25,000$1.13$28,250.00901,304View SEC Filing  
10/19/2015Karl JoheInsiderSell25,000$1.23$30,750.00926,304View SEC Filing  
10/12/2015Karl JoheInsiderSell25,000$1.31$32,750.00951,304View SEC Filing  
10/5/2015Karl JoheInsiderSell25,000$1.26$31,500.00976,304View SEC Filing  
9/28/2015Karl JoheInsiderSell25,000$1.64$41,000.001,001,304View SEC Filing  
9/21/2015Karl JoheInsiderSell25,000$1.52$38,000.001,026,304View SEC Filing  
9/2/2014Karl JoheInsiderSell6,000$4.09$24,540.00View SEC Filing  
8/1/2014Karl JoheInsiderSell6,000$2.78$16,680.00View SEC Filing  
7/1/2014Karl JoheInsiderSell6,000$4.17$25,020.00View SEC Filing  
6/2/2014Karl JoheInsiderSell6,000$4.25$25,500.00View SEC Filing  
5/5/2014William Clyde OldakerDirectorBuy15,235$3.50$53,322.50View SEC Filing  
4/22/2014Richard GarrCEOSell7,000$4.25$29,750.00View SEC Filing  
4/1/2014Karl JoheInsiderSell6,000$4.11$24,660.00View SEC Filing  
3/20/2014Karl JoheInsiderSell6,000$4.04$24,240.00View SEC Filing  
10/18/2013Karl JoheInsiderSell10,000$2.44$24,400.00View SEC Filing  
9/20/2013Karl JoheInsiderSell10,000$2.62$26,200.00View SEC Filing  
9/19/2013Karl JoheInsiderSell10,000$2.61$26,100.00View SEC Filing  
8/20/2013Karl JoheInsiderSell20,000$1.55$31,000.00View SEC Filing  
7/22/2013Karl JoheInsiderSell12,800$1.62$20,736.00View SEC Filing  
6/20/2013Karl JoheInsiderSell12,800$1.40$17,920.00View SEC Filing  
6/7/2013Richard GarrCEOSell6,000$1.42$8,520.00View SEC Filing  
5/20/2013Karl JoheInsiderSell12,800$1.51$19,328.00View SEC Filing  
2/25/2013Richard GarrCEOSell12,000$1.15$13,800.00View SEC Filing  
11/20/2012Karl JoheInsiderSell12,800$1.00$12,800.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Neuralstem (NASDAQ CUR) News Headlines

Source:
DateHeadline
Biotech Stocks Research Reports Released on OvaScience, Pacific ... - PR Newswire (press release)Biotech Stocks' Research Reports Released on OvaScience, Pacific ... - PR Newswire (press release)
www.prnewswire.com - February 14 at 3:31 PM
Neuralstem to Participate at The Young Jewish Professionals CEO ... - GlobeNewswire (press release)Neuralstem to Participate at The Young Jewish Professionals CEO ... - GlobeNewswire (press release)
globenewswire.com - February 8 at 3:27 PM
Neuralstem to Participate at The Young Jewish Professionals CEO Healthcare SymposiumNeuralstem to Participate at The Young Jewish Professionals CEO Healthcare Symposium
feeds.benzinga.com - February 8 at 7:45 AM
Neuralstem - Burning Cash, Looking For Answers - Seeking AlphaNeuralstem - Burning Cash, Looking For Answers - Seeking Alpha
seekingalpha.com - February 8 at 6:53 AM
Financial Review: Innocoll (INNL) versus Neuralstem (CUR)Financial Review: Innocoll (INNL) versus Neuralstem (CUR)
www.americanbankingnews.com - January 30 at 3:18 PM
Neuralstem to Participate at Cell and Gene Therapy World - GlobeNewswire (press release)Neuralstem to Participate at Cell and Gene Therapy World - GlobeNewswire (press release)
globenewswire.com - January 22 at 8:25 AM
Neuralstem (CUR) Price Target Cut to $1.91 by Analysts at S&P Equity ResearchNeuralstem (CUR) Price Target Cut to $1.91 by Analysts at S&P Equity Research
www.americanbankingnews.com - January 11 at 4:08 PM
Neuralstem to Present at The Neuroscience Innovation Forum for BD&L and Investment in Therapeutics and Technology - GlobeNewswire (press release)Neuralstem to Present at The Neuroscience Innovation Forum for BD&L and Investment in Therapeutics and Technology - GlobeNewswire (press release)
globenewswire.com - January 7 at 10:44 PM
Neuralstem to Present at The Neuroscience Innovation Forum for BD&L and Investment in Therapeutics and TechnologyNeuralstem to Present at The Neuroscience Innovation Forum for BD&L and Investment in Therapeutics and Technology
finance.yahoo.com - January 6 at 9:32 AM
Neuralstem to Present at The Neuroscience Innovation Forum for BD&L and Investment in Therapeutics and TechnologyNeuralstem to Present at The Neuroscience Innovation Forum for BD&L and Investment in Therapeutics and Technology
feeds.benzinga.com - January 5 at 6:50 PM
Neuralstem, Inc. (CUR) Sees Significant Increase in Short InterestNeuralstem, Inc. (CUR) Sees Significant Increase in Short Interest
www.americanbankingnews.com - December 31 at 4:22 AM
Financial Review: Neuralstem (CUR) vs. Emergent Biosolutions (EBS)Financial Review: Neuralstem (CUR) vs. Emergent Biosolutions (EBS)
www.americanbankingnews.com - December 30 at 9:12 AM
ETFs with exposure to Neuralstem, Inc. : December 26, 2017ETFs with exposure to Neuralstem, Inc. : December 26, 2017
finance.yahoo.com - December 28 at 1:37 PM
Neuralstem (CUR) Appoints Xi Chen PhD to BoardNeuralstem (CUR) Appoints Xi Chen PhD to Board
www.streetinsider.com - December 20 at 9:32 AM
Today’s Research Reports on Trending Tickers: Geron Corporation and Neuralstem, Inc.Today’s Research Reports on Trending Tickers: Geron Corporation and Neuralstem, Inc.
finance.yahoo.com - December 8 at 9:31 AM
ETFs with exposure to Neuralstem, Inc. : December 7, 2017ETFs with exposure to Neuralstem, Inc. : December 7, 2017
finance.yahoo.com - December 7 at 5:44 PM
Neuralstem Inc. (CUR) Surged To A 4-Month High On Study ResultsNeuralstem Inc. (CUR) Surged To A 4-Month High On Study Results
www.rttnews.com - December 6 at 9:40 AM
800%+ Revenue Growth Could Imply 200-300% Returns for This Small Cap Stock800%+ Revenue Growth Could Imply 200-300% Returns for This Small Cap Stock
finance.yahoo.com - December 6 at 9:40 AM
Neuralstem (CUR) Announces Positive Updated Data from Phase 2 Study of NSI-189 in Major Depressive DisorderNeuralstem (CUR) Announces Positive Updated Data from Phase 2 Study of NSI-189 in Major Depressive Disorder
www.streetinsider.com - December 5 at 5:15 PM
Neuralstem, Inc. (CUR): Updated Phase II Trial Success in Major Depressive Disorder Takes the Street by StormNeuralstem, Inc. (CUR): Updated Phase II Trial Success in Major Depressive Disorder Takes the Street by Storm
finance.yahoo.com - December 5 at 5:15 PM
Does Neuralstem Inc’s (CUR) Past Performance Indicate A Stronger Future?Does Neuralstem Inc’s (CUR) Past Performance Indicate A Stronger Future?
finance.yahoo.com - November 30 at 5:14 PM
Contrasting Neuralstem (CUR) and The CompetitionContrasting Neuralstem (CUR) and The Competition
www.americanbankingnews.com - November 18 at 11:14 AM
Neuralstem (CUR) Reports Presentation of Clinical Data for NSI-189 in Major Depressive Disorder at at ACNP MeetingNeuralstem (CUR) Reports Presentation of Clinical Data for NSI-189 in Major Depressive Disorder at at ACNP Meeting
www.streetinsider.com - November 17 at 1:37 PM
Neuralstem Announces Presentation of Clinical Data for NSI-189 in Major Depressive Disorder at the Upcoming American College of Neuropsychopharmacology Annual MeetingNeuralstem Announces Presentation of Clinical Data for NSI-189 in Major Depressive Disorder at the Upcoming American College of Neuropsychopharmacology Annual Meeting
finance.yahoo.com - November 16 at 6:17 PM
Comparing Sophiris Bio (SPHS) & Neuralstem (CUR)Comparing Sophiris Bio (SPHS) & Neuralstem (CUR)
www.americanbankingnews.com - November 14 at 5:18 AM
Neuralstem Reports Third Quarter 2017 Fiscal Results and Provides Clinical and Business Update - GlobeNewswire (press release)Neuralstem Reports Third Quarter 2017 Fiscal Results and Provides Clinical and Business Update - GlobeNewswire (press release)
globenewswire.com - November 13 at 9:13 PM
Neuralstem Reports Third Quarter 2017 Fiscal Results and Provides Clinical and Business UpdateNeuralstem Reports Third Quarter 2017 Fiscal Results and Provides Clinical and Business Update
finance.yahoo.com - November 13 at 12:41 PM
Neuralstem reports 3Q lossNeuralstem reports 3Q loss
finance.yahoo.com - November 13 at 12:41 PM
ETFs with exposure to Neuralstem, Inc. : November 10, 2017ETFs with exposure to Neuralstem, Inc. : November 10, 2017
finance.yahoo.com - November 10 at 5:35 PM
Neuralstem (CUR) Names Dr. David Recker as Chief Medical Officer - StreetInsider.comNeuralstem (CUR) Names Dr. David Recker as Chief Medical Officer - StreetInsider.com
www.streetinsider.com - November 10 at 7:26 AM
Neuralstem, Inc. :CUR-US: Earnings Analysis: Q3, 2017 By the Numbers : November 9, 2017Neuralstem, Inc. :CUR-US: Earnings Analysis: Q3, 2017 By the Numbers : November 9, 2017
finance.yahoo.com - November 10 at 7:26 AM
Neuralstem Strengthens Executive Leadership Team with Appointment of Dr. David Recker as Chief Medical OfficerNeuralstem Strengthens Executive Leadership Team with Appointment of Dr. David Recker as Chief Medical Officer
finance.yahoo.com - November 9 at 12:11 AM
Neuralstem, Inc. (CUR) Scheduled to Post Earnings on MondayNeuralstem, Inc. (CUR) Scheduled to Post Earnings on Monday
www.americanbankingnews.com - October 30 at 10:22 AM
Head to Head Analysis: Neos Therapeutics (NEOS) and Neuralstem (CUR)Head to Head Analysis: Neos Therapeutics (NEOS) and Neuralstem (CUR)
www.americanbankingnews.com - October 20 at 2:10 PM
One Thing To Consider Before Buying Neuralstem Inc (CUR)One Thing To Consider Before Buying Neuralstem Inc (CUR)
finance.yahoo.com - October 17 at 6:24 PM
Neuralstem, Inc. (CUR) Sees Large Drop in Short InterestNeuralstem, Inc. (CUR) Sees Large Drop in Short Interest
www.americanbankingnews.com - October 14 at 2:04 AM
Neuralstem: Stock falls in July on Phase II Miss, Gets 2 New Patents for Neural Stem CellsNeuralstem: Stock falls in July on Phase II Miss, Gets 2 New Patents for Neural Stem Cells
finance.yahoo.com - October 3 at 6:56 AM
Neuralstem Announces the Appointment of Two New Members to the Board of DirectorsNeuralstem Announces the Appointment of Two New Members to the Board of Directors
finance.yahoo.com - September 25 at 4:08 PM
ETFs with exposure to Neuralstem, Inc. : September 22, 2017ETFs with exposure to Neuralstem, Inc. : September 22, 2017
finance.yahoo.com - September 22 at 4:41 PM
ETFs with exposure to Neuralstem, Inc. : September 12, 2017ETFs with exposure to Neuralstem, Inc. : September 12, 2017
finance.yahoo.com - September 11 at 11:28 PM
Intra-Cellular Leaps; Schizophrenia Drug Shows Less Side Effects-Biotech Movers - TheStreet.comIntra-Cellular Leaps; Schizophrenia Drug Shows Less Side Effects-Biotech Movers - TheStreet.com
www.thestreet.com - September 7 at 10:45 PM
Neuralstem (CUR) Reports Issuance of Two US Patents - StreetInsider.comNeuralstem (CUR) Reports Issuance of Two US Patents - StreetInsider.com
www.streetinsider.com - September 7 at 10:45 PM
Neuralstem (CUR) Reports Issuance of Two U.S. PatentsNeuralstem (CUR) Reports Issuance of Two U.S. Patents
www.streetinsider.com - September 7 at 5:44 PM
Neuralstem Announces Issuance of Two U.S. PatentsNeuralstem Announces Issuance of Two U.S. Patents
finance.yahoo.com - September 7 at 5:44 PM
ETFs with exposure to Neuralstem, Inc. : August 31, 2017ETFs with exposure to Neuralstem, Inc. : August 31, 2017
finance.yahoo.com - August 31 at 10:34 PM
Neuralstem, Inc. (CUR) Short Interest UpdateNeuralstem, Inc. (CUR) Short Interest Update
www.americanbankingnews.com - August 29 at 1:06 AM
Neuralstem, Inc. :CUR-US: Earnings Analysis: Q2, 2017 By the Numbers : August 24, 2017Neuralstem, Inc. :CUR-US: Earnings Analysis: Q2, 2017 By the Numbers : August 24, 2017
finance.yahoo.com - August 24 at 5:51 PM
Head-To-Head Review: Neuralstem (CUR) & AMAG Pharmaceuticals (AMAG)Head-To-Head Review: Neuralstem (CUR) & AMAG Pharmaceuticals (AMAG)
www.americanbankingnews.com - August 22 at 8:26 PM
Neuralstem, Inc. (CUR) Issues  Earnings Results, Beats Expectations By $9.10 EPSNeuralstem, Inc. (CUR) Issues Earnings Results, Beats Expectations By $9.10 EPS
www.americanbankingnews.com - August 9 at 5:54 PM
Neuralstem Reports Second Quarter 2017 Fiscal Results and Provides Clinical and Business UpdateNeuralstem Reports Second Quarter 2017 Fiscal Results and Provides Clinical and Business Update
www.nasdaq.com - August 8 at 10:21 PM

SEC Filings

Neuralstem (NASDAQ:CUR) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Neuralstem (NASDAQ:CUR) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Neuralstem (NASDAQ CUR) Stock Chart for Saturday, February, 24, 2018

Loading chart…

This page was last updated on 2/24/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.